Articles by The Wall Street Analyzer

About The Wall Street Analyzer
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.
No Picture
News Feed

Citius Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19

July 23, 2020 The Wall Street Analyzer 1

– Pulmonology opinion leaders in ARDS therapies will bring invaluable insight in Company’s clinical trial design CRANFORD, N.J., July 22, 2020 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“CITIUS”) (“Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing and […]

CEO Interviews

Victoria Gold Corp (TSX: VGCX)(OTC: VITFF) Interview Update with CEO John McConnell

July 2, 2020 The Wall Street Analyzer Comments Off on Victoria Gold Corp (TSX: VGCX)(OTC: VITFF) Interview Update with CEO John McConnell

WSA caught up with VIT to discuss progress since their previous interview from September 2019. The company has since uplisted to the TSX and reached commercial production on their Eagle Gold Mine in the Yukon, Canada. They have also completed a 23 million public offering and seen the stock nearly triple in the last 3 months. […]

News Feed

HAPPY CANADA DAY – VICTORIA GOLD DECLARES COMMERCIAL PRODUCTION AT THE EAGLE GOLD MINE, YUKON, CANADA

July 1, 2020 The Wall Street Analyzer Comments Off on HAPPY CANADA DAY – VICTORIA GOLD DECLARES COMMERCIAL PRODUCTION AT THE EAGLE GOLD MINE, YUKON, CANADA

Whitehorse, YT / July 1, 2020 / Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is pleased to provide an update regarding commercial production and Covid-19 protocols as production continues at the Eagle Gold Mine […]

News Feed

Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

June 24, 2020 The Wall Street Analyzer Comments Off on Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

PRINCETON, N.J., June 24, 2020 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced […]